True Wealth Design
SPRY icon

True Wealth Design’s ARS Pharmaceuticals SPRY Stock Holding History

True Wealth Design’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$384 Buy
+89
New +$520 ﹤0.01% 2210
2025
Q3 		– Sell
-21
Closed -$367 – 2873
2025
Q2 		$367 Hold
21
– – ﹤0.01% 1860
2025
Q1 		$265 Buy
+21
New +$253 ﹤0.01% 1834

Other funds holding SPRY

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Norman Fields Gottscho Capital Management
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
USAdvisors Wealth Management
USAdvisors Wealth Management Eden Prairie, Minnesota $351M AUM 13.01% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
CX Institutional
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

True Wealth Design's SPRY Position: Q3 2026 in Review

True Wealth Design opened a new position in ARS Pharmaceuticals (SPRY) in Q3 2026: 89 shares worth $384. The stake represents ﹤0.01% of the portfolio and ranks #2210 among its holdings. This is a return to the name: True Wealth Design previously reported a position in SPRY as recently as Q2 2025.

True Wealth Design first reported a position in SPRY in Q1 2025 and has held it in 3 quarters since. 17 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • True Wealth Design held 89 shares of ARS Pharmaceuticals worth $384 as of Q3 2026.
  • ARS Pharmaceuticals was a new True Wealth Design position in Q3 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2210 holding.
  • True Wealth Design first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 17 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.